Cargando…
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Since 2010, several treatment options have been available for men with metastatic castration-resistant prostate cancer (mCRPC), including immunotherapeutic agents, although the clinical benefit of these agents remains inconclusive in unselected mCRPC patients. In recent years, however, immunotherapy...
Autores principales: | Ruiz de Porras, Vicenç, Pardo, Juan Carlos, Notario, Lucia, Etxaniz, Olatz, Font, Albert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124759/ https://www.ncbi.nlm.nih.gov/pubmed/33946818 http://dx.doi.org/10.3390/ijms22094712 |
Ejemplares similares
-
Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
por: Pardo, Juan Carlos, et al.
Publicado: (2020) -
PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020) -
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
por: Martori, Clara, et al.
Publicado: (2022) -
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023) -
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
por: Pardo, Juan C., et al.
Publicado: (2022)